
Nanoparticles coated in an antigen stick to red blood cells strongly enough to resist being sheared off in the lungs, allowing them to reach the spleen and be passed off to immune cells, initiating an antigen-specific immune response. Credit: Wyss Institute at Harvard University
New platform technology uses red blood cells to generate targeted immune responses in mice
Red blood cells do more than shuttle oxygen from our lungs to our organs: they also help the body fight off infections by capturing pathogens on their surfaces, neutralizing them, and presenting them to immune cells in the spleen and liver.
A team of researchers from Harvard’s Wyss Institute for Biologically Inspired Engineering and John A. Paulson School of Engineering and Applied Sciences (SEAS) has harnessed this innate ability to build a platform technology that uses red blood cells to deliver antigens to antigen-presenting cells (APCs) in the spleen, generating an immune response.
This approach successfully slowed the growth of cancerous tumors in mice, and could also be used as a biocompatible adjuvant for a variety of vaccines. The technology, called Erythrocyte-Driven Immune Targeting (EDIT), is reported this week in PNAS.
“The spleen is one of the best organs in the body to target when generating an immune response, because it is one of the few organs where red and white blood cells naturally interact,” said senior author Samir Mitragotri, a Wyss Core Faculty member who is also the Hiller Professor of Bioengineering and Hansjörg Wyss Professor of Biologically Inspired Engineering at SEAS. “Red blood cells’ innate ability to transfer attached pathogens to immune cells has only recently been discovered, and this study unlocks the door to an exciting array of future developments in the field of using human cells for disease treatment and prevention.”
A ‘check me out’ signal
Using red blood cells as delivery vehicles for drugs is not a new idea, but the vast majority of existing technologies target the lungs, because their dense network of capillaries causes cargoes to shear off of red blood cells as they squeeze through the tiny vessels. Mitragotri’s research team first needed to figure out how to get antigens to stick to red blood cells strongly enough to resist shearing off and reach the spleen.
They coated polystyrene nanoparticles with ovalbumin, an antigenic protein known to cause a mild immune response, then incubated them with mouse red blood cells. The ratio of 300 nanoparticles per blood cell resulted in the greatest number of nanoparticles bound to the cells, retention of about 80 percent of the nanoparticles when the cells were exposed to the shear stress found in lung capillaries, and moderate expression of a lipid molecule called phosphatidyl serine (PS) on the cells’ membranes.
“A high level of PS on red blood cells is essentially an ‘eat me’ signal that causes them to be digested by the spleen when they are stressed or damaged, which we wanted to avoid. We hoped that a lower amount of PS would instead temporarily signal ‘check me out’ to the spleen’s APCs, which would then take up the red blood cells’ antigen-coated nanoparticles without the cells themselves getting destroyed,” said Anvay Ukidve, a graduate student in the Mitragotri lab and co-first author of the paper.
To test that hypothesis, the team injected red blood cells coated with their nanoparticles into mice, then tracked where they accumulated in their bodies. Twenty minutes after injection, more than 99 percent of the nanoparticles had been cleared from the animals’ blood, and more nanoparticles were present in their spleens than their lungs.
The higher nanoparticle accumulation in the spleen persisted for up to 24 hours and the number of EDIT red blood cells in the circulation remained unchanged, showing that the red blood cells had successfully delivered their cargoes to the spleen without being destroyed.
Effective, adjuvant-free vaccines
Having confirmed that their nanoparticles were successfully delivered to the spleen in vivo, the researchers next evaluated whether the antigens on the nanoparticles’ surfaces induced an immune response.
Mice were injected with EDIT once a week for three weeks, and then their spleen cells were analyzed. Treated mice displayed eight-fold and 2.2-fold more T cells displaying the delivered ovalbumin antigen than mice that were given “free” nanoparticles or were untreated, respectively. Mice treated with EDIT also produced more antibodies against ovalbumin in their blood than either of the other groups of mice.
To see if these EDIT-induced immune responses could potentially prevent or treat disease, the team repeated their three-week prophylactic injection of EDIT into mice, then inoculated them with lymphoma cells that expressed ovalbumin on their surfaces.
The mice that received EDIT had about three-fold slower tumor growth compared with the control group and the group that received free nanoparticles, and had lower numbers of viable cancerous cells. This outcome significantly increased the window of time during which the tumor could be treated before the mice succumbed to the disease.
“EDIT essentially is an adjuvant-free vaccine platform. Part of the reason why vaccine development today takes so long is that foreign adjuvants delivered along with an antigen have to go through a full clinical safety trial for each new vaccine,” said Zongmin Zhao, a postdoctoral fellow in the Mitragotri lab and co-first author of the paper. “Red blood cells have been safely transfused into patients for centuries, and their ability to enhance immune responses could make them a safe alternative to foreign adjuvants, increasing the efficacy of vaccines and speed of vaccine creation.”
The team is continuing to work on understanding exactly how an immune response that is specific to the antigen presented by EDIT is generated by the spleen’s APCs, and plans to test it with other antigens beyond ovalbumin. They hope to use this additional insight to drive their pursuit of the optimal clinical setting(s) for the technology.
“The human body is a treasure trove of elegant solutions to healthcare problems, and while medicine has come a long way in understanding those mechanisms, we are still in the early stages of being able to harness them to improve the length and quality of human life. This research is an exciting step forward toward that goal, and could dramatically change how immune responses are modulated in patients,” said the Wyss Institute’s Founding Director Donald Ingber, who is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children’s Hospital, and professor of bioengineering at SEAS.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Erythrocyte-Driven Immune Targeting
- Covid-19 Live Updates: U.S. Surpasses 500,000 Covid-19 Deaths, a Monumental Losson February 22, 2021 at 5:47 pm
President Biden and Vice President Harris marked the staggering death toll with a moment of silence. In Britain, officials outlined a cautious plan to reopen schools in England.
- Immune System May Keep Tabs on the Brain From Afaron February 21, 2021 at 10:16 pm
The findings in the journal Cell open up the possibility of targeting immune cells at such surveillance sites as a means of treating conditions driven by brain inflammation. “Every organ in the ...
- Modeling New Drug Options, Better Look At Immune Response, Impact of Chromosome 12: COVID-19 Updateson February 18, 2021 at 10:02 pm
Specialized cells in a child’s immune system rapidly target SARS-CoV-2, nasal antiviral blocks transmission in ferrets, machine learning used for drug repurposing, insight into how the virus attacks ...
- Elicio Therapeutics Secures a Total of $73 Million in Series B Financingon February 17, 2021 at 5:45 am
Elicio Therapeutics, a private biotechnology company developing a pipeline of potent immunotherapies based on its proprietary lymph node targeting technology, announced the successful completion of ...
- Persistence of self-reactive CD8+ T cells in the CNS requires TOX-dependent chromatin remodelingon February 12, 2021 at 3:28 am
The transcriptional adaptation processes of harmful self-reactive CD8+ T cells in the central nervous system are not well understood. Here the authors use a system in which self-reactive and virally ...
Go deeper with Google Headlines on:
Erythrocyte-Driven Immune Targeting
Go deeper with Bing News on:
Better vaccines
- Modified COVID-19 vaccines may get nod from FDA without repeating full trialson February 22, 2021 at 7:30 pm
COVID-19 vaccines adapted for new coronavirus variants can receive authorization from the Food and Drug Administration without repeating full clinical trials.
- Iran: Results suggest primary COVID vaccine 90-percent effectiveon February 22, 2021 at 7:24 pm
Iran says its first locally manufactured vaccine has exhibited better-than-expected results in preliminary testing.
- 'This summer is going to be better:' DeWine is optimistic as Ohio confirms 11 cases of coronavirus varianton February 22, 2021 at 7:10 pm
Summer 2021 could look much different than summer 2020 – if Ohioans continue to use safety precautions and new COVID-19 variants don't threaten plans.
- Our Best Shot: Should you wait for a better vaccine?on February 22, 2021 at 6:12 pm
Vaccinating against COVID-19 is the easiest way for Australians to get their normal lives back, but millions are hesitant to get the jab.
- Over 1,200 wasted COVID-19 vaccine doses since Mass. vaccine rollout beganon February 22, 2021 at 5:29 pm
Western Mass News is your vaccine authority. Western Mass News has learned more than 1,000 doses of the COVID-19 vaccine have been thrown away since the rollout began. State officials said there have ...